Biotechnology Contract Manufacturing Market to Grow with a CAGR of 7.48% through 2029

Rising biosimilars market growth are expected to drive the Global Biotechnology Contract Manufacturing Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Biotechnology Contract Manufacturing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Biotechnology Contract Manufacturing Market stood at USD 22.15 Billion in 2023 and is anticipated to grow with a CAGR of 7.48% through 2029. The rising global demand for biopharmaceutical products is a significant driver for the contract manufacturing market. Biopharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based treatments, are increasingly popular due to their effectiveness in treating a wide range of conditions, from cancer to rare genetic disorders. As a result, biotechnology companies are expanding their production capabilities to meet market demands, often collaborating with Contract Manufacturing Organizations (CMOs) to leverage their specialized manufacturing expertise. The increasing prevalence of chronic diseases and the introduction of innovative biologics are driving the need for biopharmaceuticals, thereby stimulating the growth of contract manufacturing services.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Biotechnology Contract Manufacturing Market”

The Global Biotechnology Contract Manufacturing Market is segmented into service, scale of operation, type, therapeutic area, regional distribution, and company. 

Based on scale of operation, Commercial Operations emerged as the dominant segment in the Global Biotechnology Contract Manufacturing Market in 2023. Commercial operations encompass a broad spectrum of activities crucial for bringing pharmaceutical products to market. This encompasses marketing, sales, distribution, and post-market surveillance, all of which are pivotal for the success of any pharmaceutical product. Contract Manufacturing Organizations (CMOs) play a significant role in supporting these operations by providing reliable and efficient manufacturing services. This allows pharmaceutical companies to focus on commercializing their products without the burden of manufacturing logistics. Contract manufacturing typically aligns more closely with commercial activities rather than clinical ones. Clinical operations involve the planning, management, and execution of clinical trials, which are essential for proving the safety and efficacy of pharmaceutical products, typically occurring earlier in the drug development process. Once a product successfully completes clinical trials and obtains regulatory approval, the focus shifts towards commercialization and scaling up manufacturing to meet market demand. This transition underscores the critical role of commercial operations and the corresponding need for robust contract manufacturing partnerships. The commercial success of pharmaceutical products relies heavily on timely market entry and effective supply chain management. CMOs specializing in commercial manufacturing excel at navigating regulatory requirements, optimizing production processes, and ensuring consistent product quality—essential for meeting commercial timelines and maintaining market competitiveness. Pharmaceutical companies often prioritize establishing strong partnerships with CMOs proficient in commercial operations to streamline the commercialization process and maximize market opportunities.

Based on region, Asia Pacific emerged as the fastest growing region in the Global Biotechnology Contract Manufacturing Market in 2023. Countries across the Asia Pacific region offer competitive manufacturing costs compared to regions such as North America and Europe, making them attractive destinations for pharmaceutical and biotechnology firms seeking to outsource manufacturing tasks to Contract Manufacturing Organizations (CMOs) in the area. Additionally, the Asia Pacific region benefits from a vast reservoir of skilled scientific and technical professionals, vital for executing intricate manufacturing procedures and ensuring top-notch production standards within the biotechnology sector. The biotechnology industry in this region is experiencing rapid expansion, propelled by escalating investments in research and development, favorable governmental regulations, and escalating demand for biopharmaceuticals. This surge in growth presents lucrative opportunities for contract manufacturing services to cater to the production requirements of biotech enterprises. Furthermore, many nations in the Asia Pacific region have established regulatory frameworks conducive to biopharmaceutical manufacturing, characterized by streamlined processes and supportive governmental policies. These factors collectively stimulate investment in contract manufacturing infrastructure, thereby fueling market expansion.

Major companies operating in Global Biotechnology Contract Manufacturing Market are:

·         Lonza Group Ltd. 

·         Thermo Fisher Scientific, Inc.

·         Wuxi Biologics Co., Ltd. 

·         Catalent, Inc.

·         Samsung Biologics Co., Ltd. 

·         Boehringer Ingelheim International GmbH

·         Fujifilm Holdings Corporation

·         Abbvie Inc. 

·         Eurofins Scientific SE

·         Genscript Biotech Corporation

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Global Biotechnology Contract Manufacturing Market is poised for significant growth in the coming years. The rising focus on personalized medicine and cell therapies, driven by advancements in genomics and regenerative medicine, is expected to fuel demand for specialized manufacturing services. Additionally, the urgency for pandemic preparedness and the global demand for treatments for infectious diseases, highlighted by the COVID-19 pandemic, will further drive market expansion. North America, along with emerging markets in Asia, is forecasted to play substantial roles in this growth trajectory. North America will leverage its established biotech sectors, while Asian markets will capitalize on their cost-effective production capacities to sustain market momentum”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Biotechnology Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service (Manufacturing, Formulation and Fill-Finish, Packaging and Labeling, Other services), By Type (Biologic Drug Substance Manufacturing, Biologic Drug Product Manufacturing) , By Scale of Operation (Commercial Operations, Clinical Operations), By Therapeutic Area (Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Neurology, Other Therapeutic Areas), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Biotechnology Contract Manufacturing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Biotechnology Contract Manufacturing Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com